Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced notable stock volatility on June 17, 2026, with a significant decline. Over the past week and month, the stock has dropped sharply, and year-to-date performance shows a substantial decrease. The company has reported negative results for four consecutive quarters, indicating ongoing financial challenges.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a significant stock decline, contrasting with the broader market's performance. Over the past week and month, the company has experienced substantial downturns, with ongoing negative financial metrics, including a considerable net loss and declining sales growth, indicating operational challenges.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market's slight decrease. The company has struggled significantly over the past month and year-to-date, reporting substantial losses and negative financial metrics, including a net profit decline and low operating cash flow.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. saw a notable decline in its stock price, contrasting with the China Shanghai Composite's modest decrease. The company has faced ongoing financial challenges, including negative returns and consecutive quarterly losses, contributing to a significant year-to-date drop in its stock value.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. saw a notable increase in its stock today, contrasting with the broader market's performance. However, the company has struggled over the past year, with significant declines in net sales and operating profit, alongside consecutive quarterly losses. Its market capitalization is CNY 34,444 million.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a notable stock decline, significantly underperforming compared to the broader market. The company reported a substantial net loss and declining sales, raising concerns about its financial health and long-term growth prospects despite previous gains over the past three years.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a notable stock decline today, reaching an intraday low. Over the past week and month, the stock has continued to decrease, with significant year-to-date losses. The company reported a substantial net profit decline and negative operating cash flow, indicating ongoing financial challenges.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. saw a significant intraday increase on March 27, 2026, contrasting with the broader market's modest gains. Despite a notable year-over-year growth, the company faces challenges such as a high debt-to-equity ratio and operating losses, with a market capitalization of CNY 40,221 million.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. saw a notable stock price decline today, contrasting with the broader market's performance. The company has faced significant decreases over the past week and month, with year-to-date losses reflecting ongoing challenges in its financial fundamentals and market position within the pharmaceuticals sector.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market. The company has experienced significant short-term losses, while its annual return remains strong. However, concerns about its financial health persist, including high debt levels and declining net sales.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with the broader market's modest gain. The company has experienced significant downturns recently, alongside operational challenges and a high debt-to-equity ratio, raising concerns about its market position in the pharmaceuticals sector.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a significant stock decline today, contrasting with the broader market. The company has experienced notable decreases in both weekly and monthly performance, alongside a substantial year-to-date downturn. High debt levels and declining net sales further complicate its financial outlook in the pharmaceuticals sector.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. faced a notable stock decline today, contrasting with the broader market. Despite a strong annual growth rate, the company has experienced significant downturns recently, alongside concerns about declining net sales and a high debt-to-equity ratio, raising questions about its financial stability.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. saw a notable stock price increase on February 25, 2026, despite a broader market decline. While the company has shown impressive annual growth, it faces challenges such as a high debt-to-equity ratio and negative return on equity amid a competitive sector.